Table 4.

Advanced therapeutic scheme in the two groups (LCIG and CSAI)

Parameter	LCIG (N = 53)	CSAI (N = 19)
Duration of infusion (h/day); mean ± SD (range)	14.1 ± 2.1 (11.0–24.0)	Not applicable
Levodopa equivalent daily dose (LEDD) (mg); mean ± SD (range)	1112.6 ± 473.4 (532–2960)	1665.3 ± 1309.0 (180–5600)
Duration of treatment (months); mean ± SD (range)	17.8 ± 9.1 (5.98–41.89)	24.7 ± 9.9 (5.65–40.15)
Patients using concomitant anti-parkinson medications during the day; N (%)	14 (26.4%)	13 (68.4%)
Number of anti-parkinson drug units/day; mean ± SD (range)	1.4 ± 0.7 (1–3)	6.7 ± 4.4 (1–19)